#alcaftadine

[daicelpharmastandard]

https://www.daicelpharmastandards.com/product/alcaftadine/alcaftadine-n-demethylated

[pharmaceutical0]

Alcaftadine | 47084-10-4 | Impurity Standards

Alcaftadine Impurity Standards

CAT. No.A1360000

CAS. No.147084-10-4

Mol. F.C19H21N3O

Mol. Wt.307.40 g/mol

[amcrasto]

ALCAFTADINE, WO 2017211246, NEW PATENT, SHENZHEN TARGETRX, INC.

Alcaftadine NEW PATENT https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2017211246&redirectedID=true WO-2017211246, SHENZHEN TARGETRX, INC. SUBSTITUTED FUSED IMIDAZOLE CYCLIC COMPOUND AND PHARMACEUTICAL COMPOSITION THEREOF WANG, Yihan; (CN). XING, Qingfeng; (CN) Novel deuterated analogs of substituted fused imidazole cyclic compounds, particularly alcaftadine are histamine H1-receptor…

[cdyduocsaigon2021]

Bạn đọc hãy cùng tìm hiểu kỹ hơn các thông tin về thuốc Alcaftadine dưới bài viết để hiểu rõ hơn tác dụng, cách dùng, liều lượng sử dụng, tác dụng phụ xảy ra, những lưu ý trong quá trình sử dụng thuốc... Theo dõi bài viết chi tiết để có thêm nhiều kiến thức y khoa hữu ích.

[pediadoc7-blog]

Alcaftadine Ophthalmic Solution Information

Medical information for Alcaftadine Ophthalmic Solution including Indication, Dosing, Adverse Effect. To know more about Alcaftadine Ophthalmic Solution read this article https://www.pediatriconcall.com/drugs/alcaftadine-ophthalmic-solution/235

[azveille]

Copycats wanted: Pfizer, AZ and more under threat as China solicits generics

The U.S. FDA compiles a list of off-patent drugs without an approved generic to encourage the development of copycats. Now, the Chinese authorities are rolling out a similar initiative, only with some extra incentives.

On Thursday, China’s National Health Commission published (Chinese) its first proposed list of 34 drugs (full list below) that the agency says are already off patent or nearing patent expiration but have no generic drug application in the country or lack competition. The plan is to invite drugmakers to make copies—and here comes the key—under drug regulator’s priority review pathway, which was until now mostly given to innovative drugs.

The list covers originators from many foreign pharmas, including Pfizer, AstraZeneca, Merck & Co., Johnson & Johnson, Roche, Bristol-Myers Squibb, Takeda, Eli Lilly, and more. And the drugs span a wide range of therapeutic areas, including HIV, anti-infectives, ophthalmology, cancer, blood and immune disorders, etc.

Some prominent names can be found on the list.

Teva’s multiple sclerosis blockbuster Copaxone, which just saw its first U.S. copycat from Mylan less than two years ago, is probably the best-selling drug on the list by global sales. Johnson & Johnson subsidiary Actelion’s pulmonary artery hypertension drug Tracleer and United Therapeutics' rival med Remodulin are both included. Roche’s CMV retinitis treatment Valcyte and chemotherapies Faslodex and Ixempra from AZ and BMS, respectively, are also among those listed.

China made certain of its intention to make that list in January. At that time, it said the government would update the list at the end of each year starting from 2020. And key small molecules and biologics on the list will also be incorporated into state-backed R&D plans.

The initiative is seen as another push by the Chinese government to bring in competition to rein in drug costs. In a recent decree, physicians are strictly not allowed to write brand names on prescriptions, and even if they do, pharmacists could fill them with generics.

Multinational firms have for a long time enjoyed strong sales from their older medicines in China, even as they suffer in developed markets like the U.S. and EU. But in a bulk procurement program being piloted in 11 major cities, these foreign bigwigs have started to feel the heat. With the scheme, drugmakers—originator and generic—bid for big supply contracts with all public hospitals in those cities. Of the final 25 contracts, foreign pharmas only won two.

Pfizer, which lost out to domestic makers with Lipitor, and AstraZeneca, which failed in its attempt at winning the Crestor tender, are both guiding slower China sales growth this year.

For the current 34-drug list, the Chinese government is opening up for public comments for five work days.

Full list of the 34 drugs by generic name:

abacavir, alcaftadine, atovaquone, azathioprine, bosentan, brivaracetam, colesevelam hydrochloride, cyclophosphamide, dapsone, deferasirox, dofetilide, eletriptan, ertapenem, fezoterodinum, formoterol fumarate, fosaprepitant, fulvestrant, glatiramer, icatibant, ixabepilone, levodopa/benserazide, levothyroxine, mercaptopurine, methotrexate, nitisinone, posaconazole, pyridostigmine, raloxifene, rilpivirine, tafluprost, tretinoin, treprostinil, valganciclovir, vigabatrin.

Editor's Note: The story has been updated to clarify that the priority review designation was previously not only given to innovative drugs. For example, a Rituxan biosimilar by Fosun Henlius was recently approved in China after being put under priority review.

[precisemarketreportsandinsights]

Ophthalmic Medication Market Size And Forecast Report 2017 By Radiant Insights,Inc

This report mainly introduces volume and value market share by players, by regions, by product type, by consumers and also their price change details. As a Detailed Analysis report, it covers all details inside analysis and opinion in Ophthalmic Medication industry.

This report splits Ophthalmic Medication market by Ophthalmic Medication, which covers the history data information from 2012 to 2016 and forecast from 2017 to 2022.

Browse Full Research Report with TOC on https://www.radiantinsights.com/research/global-ophthalmic-medication-detailed-analysis-report-2017-2022

This report focuses Global market, it covers details as following:

Major Companies

•               AKORN

•               ALCON

•               ALLERGAN

•               ASTELLAS

•               BAUSCH AND LOMB

•               DISHMAN CARBOGEN AMCIS LIMITED IN 380 009 Ahmedabad

•               FRESENIUS KABI USA

•               FUJISAWA HLTHCARE

•               GLAND PHARMA LTD

•               MERCK

•               Merck Sharp & Dohme Ltd

•               Novartis Pharma K.K.

•               SANDOZ INC

•               Santen Pharmaceutical Co., Ltd.

•               Senju Pharmaceutical Co.,Ltd.

•               Tokyo Chemical Industry Co. Ltd (TCI) JP 103-0023 Tokyo

•               VALEANT LUXEMBOURG

Request A Sample Copy of This Report at: https://www.radiantinsights.com/research/global-ophthalmic-medication-detailed-analysis-report-2017-2022/request-sample

Main Regions

•               North America

•               United States

•               Canada

•               Latin America

•               Mexico

•               Brazil

•               Argentina

•               Others

•               Europe

•               Germany

•               United Kingdom

•               France

•               Italy

•               Spain

•               Russia

•               Netherland

•               Others

•               Asia & Pacific

•               China

•               Japan

•               India

•               Korea

•               Australia

•               Southeast Asia

•               Indonesia

•               Thailand

•               Philippines

•               Vietnam

•               Singapore

•               Malaysia

•               Others

•               Africa & Middle East

•               South Africa

•               Egypt

•               Turkey

•               Saudi Arabia

•               Iran

•               Others

Main Product Type

Ophthalmic Medication Market, by Ophthalmic Medication

•               Tropicamide

•               Micafungin

•               Alcaftadine

•               Methyl Cellulose

•               Caspofungin

•               Verteporfin

•               Pirenoxine

•               Dipivefrine

•               Apraclonldine

•               Prolonium Iodide

•               Copper Citrate

Main Applications

•               Department of ophtalmology

About Radiant Insights

Radiant Insights is a platform for companies looking to meet their market research and business intelligence requirements. We assist and facilitate organizations and individuals procure market research reports, helping them in the decision making process. We have a comprehensive collection of reports, covering over 40 key industries and a host of micro markets. In addition to over extensive database of reports, our experienced research coordinators also offer a host of ancillary services such as, research partnerships/ tie-ups and customized research solutions.

Media Contact:

Michelle Thoras

201 Spear Street 1100,

Suite 3036, San Francisco,

CA 94105, United States

Tel: 1-415-349-0054

Toll Free: 1-888-928-9744

Mail: sales@radiantinsights.com

[veeprho]

[amcrasto]

LASTACAFT, ALCAFTADINE.. Drug Patent Expiration, 21st Nov 2013

ALCAFTADINE

Alcaftadine is used to prevent eye irritation brought on by allergic conjunctivitis. It…

View Post